Other metabolites (i.e., 3-OH-desogestrel, 3-OH-desogestrel, and 3-OH-5-H-desogestrel) with no pharmacologic actions also have been identified and these metabolites may undergo glucuronide and sulfate conjugation
Although currently not FDA-approved specifically for weight loss, the promising clinical outcomes have sparked widespread interest and ongoing research into its broader therapeutic uses
Innovations, such as oral formulations and dual-target agonists, are reshaping competitive positioning
For many patients, gastrointestinal side effects gradually improve as the body adapts to the medication, though the timeline varies by product and individual
Pregnancy and breastfeeding GLP-1 medications should be discontinued before pregnancy
Coimmunoprecipitation (CoIP) analysis Co-IP was performed according to an established method with minimal modifications